RETRACTED: An open-label trial comparing alendronate and alphacalcidol in reducing falls and hip fractures in disabled stroke patients.

Abstract

This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been retracted at the request of the Editor-in-Chief due to include issues around study governance (ethical oversight and funding), implausible participant recruitment, implausible study conduct and publication timelines, authorship misconduct, conflicting statements about randomization methodology, implausibly similar randomized groups, implausible results, impossible results, duplicate reporting and data errors. In addition, several other publications reporting non-randomized research by members of this group of investigators have been retracted.

• Authors: Yoshihiro Sato, Jun Iwamoto, Yoshiaki Honda
• Journal: Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association (J Stroke Cerebrovasc Dis) 2011 Jan-Feb Vol. 20 Issue 1 Pg. 41-46 ISSN: 1532-8511 [Electronic] United States
• PMID: 20598577 (Publication Type: Journal Article, Randomized Controlled Trial, Retracted Publication)
• Copyright: Copyright © 2011 National Stroke Association. Published by Elsevier Inc. All rights reserved.

Chemical References

• Bone Density Conservation Agents
• Hydroxycholecalciferols
• Calcitriol
• alfacalcidol
• Alendronate

Topics

• Accidental Falls (prevention & control)
• Aged
• Alendronate (therapeutic use)
• Bone Density
• Bone Density Conservation Agents (therapeutic use)
• Bone and Bones (metabolism, pathology)
• Calcitriol (blood)
• Disabled Persons (statistics & numerical data)
• Female
• Hip Fractures (prevention & control)
• Humans
• Hydroxycholecalciferols (therapeutic use)
• Male
• Stroke (complications)